Watch Dr Chris Baldwin, Deputy CEO & COO, as he explains Exopharm’s latest developments and potential target markets. 0:00 – Intro 0:10 – What is your business about? 1:20 – Tell us about your product developments and pipeline? 3:01 – What is the size of your potential target markets? 4:16 – What is EX1’s competitive advantage? 5:30 – How did your […]
In this webinar, Dr Ian Dixon, Exopharm’s Managing Director and Founder, discusses three recent ASX announcements and answers questions in a Q&A facilitated by Paul Hart, Executive Director of Canary Capital. The following ASX announcements are addressed: 01/04/2021 Preclinical Data from Osteoarthritis Animal Study 06/04/2021 Positive PLEXOVAL II Phase 1 Clinical Trial Results 06/04/2021 LEAP Technology- Advanced EV […]
We presented at the Twilight Investor Briefing on March 11 hosted by FB Rice and organised by Monsoon Communications. We would like to thank the organisers for the opportunity to share our exosome medicine strategy, unique technology platform and show why this is the Year We LEAP as we work to empower exosome medicine discovery […]
Early Careers in Science Webinar – Hosted by Exopharm 18 February 2021 12-12.45pm AEDT Choosing a career path can be daunting, and we understand this. Aimed at high school students, this free webinar provided some insight into a career in science and featured speakers from Exopharm who are passionate about helping students embrace this field. […]
We presented at the BIO CEO & Investor Digital Conference which is taking place from 16-18 February. Our Chief Commercial Officer, Dr. Chris Baldwin, provided insight into our company, exosomes in general and the technologies we are using to bring exosome therapeutics to the world. You can find the slide deck here.
Watch our interview at the Edison Group Open House: Global Healthcare 2021 Conference.
Producing EVs at the Clinical Scale On November 11, we presented at the Exosome Based Therapeutic Development Digital Summit. At this key exosome industry event, we had the opportunity to highlight our LEAP technology, the team’s accomplishments and our commitment to collaboration to advance the development of all exosome therapeutics. Our Chief Commercial Officer, Dr […]
Our science is too important to leave to just the scientists. On November 5, Dr Balarka Banerjee and Dr Kartini Asari explained some of the advances Exopharm is making. This science update forms part of our ‘Behind the Scenes’ webinar series. Stem Cells: Exosome Factories Dr. Balarka Banerjee, Cell Development Manager Exopharm’s unique LEAP […]
Yesterday, Chief Commercial Officer Chris Baldwin sat down with Stockhead’s resident health and biotech expert Tim Boreham for the latest episode of The Health Kick Podcast. They discuss the potential of exosomes to transform healthcare, and our journey to commercialising our exosome therapeutics. Click below to listen. You can find the full post here.
ShareCafe’s “Hidden Gems” Webinar 18 Sept 2020 Chief Commercial Officer Chris Baldwin provides updates on Exopharm’s Technology and Naive EV programs, including the addition of Alison Mew to the senior leadership and the progress on Exopharm’s second clinical trial.
Behind the Scenes with our Scientists Recently, there has been a variety of updates about the company’s business progress and accomplishments. This webinar provided a closer look at some of science and technology behind our most recent advances, Fortrexo CoV™ and Exoria™. RNAi’s to Stop Coronavirus Dr Karen Holden, Head of Translation Exopharm has […]
Exopharm CCO Dr Chris Baldwin gives a shareholder update on the ‘Morning Twilight Briefing’ webinar series hosted by Monsoon Communications. Chris discusses Exopharm’s key development areas and provides an overview of the company’s engineered EV technology.
Exopharm Webinar May 2020 – Our Strategic Response to COVID-19 Exopharm updates the public on its recent progress and activities. Hosted by Jason Watson, Chair of Exopharm, Ian Dixon (CEO), Gregor Lichtfuss (COO) and Chris Baldwin (CCO) discuss how COVID-19 has affected operations and strategies. The application of Exopharm’s engineered exosome program, Fortrexo, is discussed, […]